Naming Service - Brand Institute, inc.



			Naming Service Brand Institute is the premier full-service branding agency dedicated to strategic and innovative brand naming and identity solutions. We strive to exceed the expectations of every client by combining leading-edge market research with the highest levels of client service, integrity and brand management Pfizer reports higher Q1 earnings, lower revenue Pfizer Inc. reported better-than-expected earnings for the first quarter of 2006, but revenue fell for the period compared with the first quarter of 2005. The company attributed its higher income in part to a favorable change in the tax rate and cost savings from its restructuring. For the first quarter of 2006, net income increased to $4.11 billion, or $0.56 per diluted share, up from $301 million, or $0.04 per diluted share, in the previous year's first quarter when the firm took large charges related to the repatriation of overseas funds. Adjusted diluted earnings per share were $0.61, which exceeded the average forecast of $0.53 predicted by analysts polled by Reuters Estimates. "Pfizer beat expectations by managing their expenses and getting a favorable tax rate, so the results were not as good as they looked," Oppenheimer & Co. analyst Scott Henry said in a Reuters report. Revenue for the quarter dropped 3 percent, from $13.09 billion in 2005 to $12.66 billion. According to Reuters, the drop in revenue was partially due to competition from generics, including versions of the company's Zithromax (azithromycin) antibiotic and some of its treatments for epilepsy and hypertension. Cholesterol drug Lipitor (atorvastatin calcium) remained the company's top seller. Although sales of the drug reached $3.11 billion for the quarter, the 1 percent growth reflected by this figure was lower than expected. Despite this news, Pfizer continues to predict sales of more than $13 billion for Lipitor in 2006, "although it is an aggressive target given a challenging environment and a slower-than-hoped-for start to the year," said Hank McKinnell, Pfizer's chief executive officer. Pfizer expects to report diluted earnings per share of $1.56 to $1.60 for 2006, and it confirmed its forecasts for 2007 and 2008. Pfizer shares closed at $24.82, down $0.11, or 0.4 percent, in moderate trading on the New York Stock Exchange. Naming Service Schering-Plough's investigational thrombin receptor antagonist receives fast track designation The Food and Drug Administration granted fast track designation to Schering-Plough Corp.'s investigational oral thrombin receptor antagonist, SCH 530348. SCH 530348 is designed to modify the actions of thrombin, the most potent activator of platelets, by binding selectively to the thrombin receptor on platelets. The drug is currently in Phase II clinical development as a secondary prevention of cardiovascular morbidity and mortality outcomes in at-risk patients. The company is investigating SCH 530348 as a prophylaxis for arterial thrombosis in patients with acute coronary syndrome, those with existing peripheral arterial disease and patients with prior myocardial infarction or stroke. Researchers are investigating whether the drug has potential to provide clinical benefit without an increased risk of bleeding. Naming Service Ortho-McNeil's Axert reduces migraine symptoms, meta-analysis shows A meta-analysis of four clinical trials showed that all dosages of Ortho-McNeil Neurologics Inc.'s Axert (almotriptan malate) were significantly more effective in eliminating migraine-associated symptoms than was placebo. A total of 2,294 patients (1,908 in the Axert groups and 386 in the placebo groups) were included in the four randomized, placebo-controlled, double-blind trials. The primary objective of this meta-analysis was to examine the efficacy, speed of onset and tolerability of Axert in the acute treatment of migraine. Axert 12.5 mg was significantly more effective than placebo for pain relief and pain freedom as soon as 30 minutes after dosing. At two hours, the pain relief rate for those treated with placebo was 35 percent compared with 56 percent, 63.7 percent and 66 percent for the Axert 6.25 mg, 12.5 mg and 25 mg groups, respectively. The pain-free rates at two hours in the Axert groups were 26.7 percent, 36.4 percent and 43.4 percent, respectively, while the pain-free rate was 13.9 percent for the placebo group. For the two smaller dosages of Axert, the number of adverse events was not significantly different from that of placebo. According to the authors, these results confirmed findings from earlier individual trials, but they also showed, for the first time, significant pain-free efficacy at 30 minutes compared with placebo. The study was published in the April issue of the journal Cephalalgia. Naming Service Abbott's Q1 results show increase in net earnings, decrease in sales Abbott's quarterly net earnings increased 3.2 percent, while net sales decreased 3.7 percent from the corresponding quarter of 2005. Net earnings increased to $864.9 million, or $0.56 per diluted share, up from $837.9 million, or $0.53 per diluted share, in the first quarter of 2005. Net sales for the first quarter decreased 3.7 percent to $5.18 billion compared with $5.38 billion in the previous year's same quarter. U.S. pharmaceutical sales decreased 22.6 percent in the first quarter of 2006 to $1.45 billion. Abbott noted that the discontinuation of the co-promotion and distribution of Boehringer Ingelheim GmbH's Mobic (meloxicam), a pain drug, Flomax (tamsulosin hydrochloride), a treatment for enlarged prostates, and Micardis (telmisartan), a blood pressure treatment, affected the company's sales growth. Adjusted sales for the quarter increased by 7.9 percent. For the second quarter of 2006, Abbott announced guidance of $0.58 to $0.60 per share. Abbott also noted its full-year earnings per share are expected to be $2.46 to $2.52 per share. Abbott shares closed at $41.34, down $0.34, or 0.8 percent, in moderate trading on the New York Stock Exchange. Naming Service Schering AG reports preliminary Q1 results Schering AG's revenue increased in the first quarter of this year compared with the same period in 2005, driven primarily by growth of the multiple sclerosis treatment Betaseron (interferon beta-1b) and the birth control pill Yasmin (drospirenone/ethinyl estradiol). For the first quarter of 2006, Schering posted a preliminary net profit of approximately $215 million, or approximately $1.14 per share, compared with approximately $186.8 million, or approximately $0.99 per share, in the same period in 2005. The company anticipates an operating profit of approximately $296.3 million for the quarter, which is lower than the average forecast of approximately $303.7 million from analysts' estimates in a Reuters poll. Net sales for the quarter reached approximately $1.74 billion compared with approximately $1.57 billion in the first quarter of 2005. For the quarter, Betaseron sales increased by 23 percent currency adjusted to approximately $286.4 million, while Yasmin sales increased 34 percent currency adjusted to approximately $222.2 million. The complete interim report for the quarter will be published on April 26, the company said. Earlier this month, Bayer AG issued an official offer to acquire Schering for approximately $19.98 billion. Schering has until the market closes on May 31 to accept the offer. Schering shares closed at $105.40, up $0.80, or 0.8 percent, in heavy trading on the New York Stock Exchange. Naming Service Amgen reports positive results in Q1 Amgen Inc. experienced a 14 percent increase in total revenue for the first quarter of 2006 and a 26 percent increase in adjusted earnings per share, excluding stock option expense. The company's net income for the first quarter of 2006 was $1 billion, or $0.82 per diluted share, compared with $854 million, or $0.67 per diluted share, in the same quarter of 2005. Adjusted net income for the quarter totaled $1.1 billion, up 19 percent from $924 million generated in the first quarter of 2005. Adjusted earnings per diluted share jumped to $0.91, up 26 percent from $0.72 in the comparable period last year. The company noted that the adjusted figures from the first quarters of 2006 and 2005 exclude certain expenses associated with the acquisitions of Immunex Corp. and Tularik Inc., stock option expenses and certain other items. For this year's first quarter, total revenue was $3.22 billion compared with $2.83 billion in the same quarter last year. The firm's performance was aided by an increase in U.S. sales of chemotherapy-induced anemia treatment Aranesp (darbepoetin alfa), which were up from $447 million in the first quarter of 2005 to $596 million in the corresponding quarter of this year. Additionally, quarterly U.S. sales of anemia drug Epogen (epoetin alfa) rose to $604 million, up from $583 million in the first quarter of 2005. Amgen expects 2006 adjusted earnings per share in the range of $3.60 to $3.70, including expected dilution of the company's acquisition of Abgenix Inc., but excluding stock option expense and certain other expenses. "We saw continued growth in our marketed products, and we completed our [Food and Drug Administration] submission for panitumumab in third-line metastatic colorectal cancer, bringing us another step closer to making this important medicine available to patients," said Kevin Sharer, Amgen's chief executive officer. "We also finalized our acquisition of Abgenix, which will allow us to fully realize the value of panitumumab as we develop this important cancer therapeutic for additional indications." title="branding company" Amgen shares closed at $68.30, down $2.67, or 3.8 percent, in heavy trading on the Nasdaq. Naming Service Naming Service Genzyme Corp. Genzyme Corp. reported first-quarter 2006 net income of $101 million, or $0.37 per diluted share, compared with $95.6 million, or $0.36 per diluted share, in the corresponding quarter of 2005. Revenue rose from $629.9 million in last year's first quarter to $730.8 million this quarter. Analysts had expected higher quarterly results, according to Reuters. "A few of our products experienced revenue growth slightly below our plan, and that, coupled with our significant rate of investment, held [earnings-per-share] growth to approximately 16 percent over the same quarter last year," said Henri Termeer, Genzyme's chief executive officer. Genzyme shares closed at $60.65, down $5.13, or 7.8 percent, in heavy trading on the Nasdaq. Naming Service Naming Service Cephalon Inc. Cephalon Inc. submitted data to the Food and Drug Administration showing that the company's Sparlon (modafinil) tablets, a potential attention deficit/hyperactivity treatment, did not cause Stevens-Johnson syndrome, a rare but serious skin rash condition, in a child participating in one of the Phase III trials for the drug. In documents filed with the Securities and Exchange Commission, Cephalon said it had reached this conclusion by discussing the case with the treating physicians and leading dermatologists, as well as by having informal discussions with the FDA. In March, the FDA's Psychopharmacologic Drugs Advisory Committee voted to not recommend Sparlon for approval because of concerns about this case of Stevens-Johnson syndrome. Naming Service Naming Service Chembio Diagnostics Inc. Chembio Diagnostics Inc. received an approvable letter from the Food and Drug Administration for its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak tests. The letter stated that the approval is subject to final review of the package inserts for the product and other standard conditions related to all Pre-Market Applications. The company anticipates FDA approval in the "very near future." title="branding company" The tests detect HIV-1 and HIV-2 antibodies in whole blood (venous or finger stick), serum and plasma, and provide results within approximately 15 minutes of application. Naming Service Naming Service MDS Nordion MDS Nordion signed a three-year contract with Bradmer Pharmaceuticals Inc. to develop and supply Neuradiab, a monoclonal antibody conjugated to iodine-131 used to treat glioblastoma multiforme, a form of brain cancer. Dr. Mark Rogers, Bradmer's chief executive officer, said the new agreement was an important part of the company's planned multicenter clinical trial for Neuradiab, which was recently granted orphan drug status by the Food and Drug Administration. Financial details of the contract were not released. Naming Service


	- advertising slogan - b2b branding - best company names - brand architecture - brand association - brand awareness - brand building - brand communication - brand communications - brand creation - brand essence - brand evaluation - brand experience - brand extension - brand extensions - brand id - brand identification - brand image - brand management - brand marketing - brand name generator - brand name product - brand name search - brand personality - brand planning - brand position - brand positioning - brand products - brand profile - brand repositioning - brand revitalization - brand strategist - brand valuation - brand value - brand values - brand vision - branded media - branding a product - branding advertising - branding campaign - branding consultancy - branding consultant - branding consulting - branding design - branding expert - branding experts - branding firm - branding firms - branding guidelines - branding ideas - branding identity - branding logos - branding process - branding products - branding research - branding strategies - branding strategy - branding tools - brandname - brandnames - business branding - business naming - business slogan - catchy slogan - change company name - changing company name - co branding - cobranding - companies name - companies names - company logo - company logos - company name change - company name creator - company name finder - company name generator - company name ideas - company name registration - company name suggestions - company taglines - company titles - conjoint analysis - consumer market research - consumer panels - consumer research - consumer survey - cool company names - corporate identity - corporate identity design - corporate internet branding - corporate logo - corporate name change - corporate name generator - corporation name - corporation names - create a company name - create company name - creating a company name - creative company names - design branding - design company names - digital branding - drug safety - fda approval - fda regulations - find company name - food package design - global branding - global market research - global panel - global survey - good company name - good company names - great company names - healthcare market research - how to choose a company name - how to name a product - how to name your company - ideas for company names - identity branding - image branding - internal branding - international market research - internet branding - internet market research - internet panel - internet poll - internet surveys - law firm names - line extension - logo branding - logo companies - logo company - logo creation - logo design - logo designer - logo designers - logo research - market research panels - market research tools - marketing branding - marketing slogan - name a company - name company - name creation - name development - name generation - name research - names for companies - naming a business - naming a company - naming a product - naming business - naming consultants - naming products - naming service - naming services - naming software - naming standards - naming strategy - naming tools - naming your business - naming your company - new company name - new company names - online market research - package designs - pharmaceutical consultants - physician survey - product brand - product launches - qualitative research - real branding - rebrand - rebranding - register a company name - register company name - registered company names - registering company name - registering company names - research panel - research panels - slogan - slogans - strategic branding - strategic name development - survey panel - survey tool - survey tools - tagline - tagline generator - trade name search - trademark - trademark search - trademark searches - trademark searching - trademarks - unique company names - visual branding - your company name


			Austin / Chicago / Geneva / London / Los Angeles / Miami / New York / Ottawa / Raleigh Durham / Rockville / San francisco / Tokyo